Tag: Cellular Immunotherapy
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
March 4, 2021
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy
January 25, 2021
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.